Excitingly, in addition to the combined anti-tumor effect of VC and anti-PD-L1, VC treatment further boosted efficacy of anti-PD-L1 combination therapy with IL-2 in both subcutaneously implanted tumor models (Fig. 9i–k) and orthotopic liver cancer models (Fig. 9l–n). This evidence concerns the gene CD274 and neoplasm.